IL4R and neoplasm: The (KLAKLAK)2 peptide fused with the IL4R-binding IL4RPep-1 peptide (CRKRLDRNC) exhibited selective cytotoxicity toward IL4R-expressing tumor cells and enhanced the sensitivity of cells to chemotherapy53.